🇺🇸 FDA
Patent

US 8394966

Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid

granted A61KA61K31/4245A61P

Quick answer

US patent 8394966 (Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid) held by PTC THERAPEUTICS, INC. expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Mar 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/4245, A61P, A61P11/00, A61P13/12